- Home
- GCDT vs CLRB Comparison
GCDT vs CLRB Comparison
Compare GCDT & CLRB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GCDT | CLRB |
|---|---|---|
| Founded | 1992 | 2002 |
| Country | Hong Kong | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.0M | 11.1M |
| IPO Year | N/A | 2008 |
Fundamental Metrics
Financial Performance| Metric | GCDT | CLRB |
|---|---|---|
| Price | $1.13 | $2.55 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $10.00 |
| AVG Volume (30 Days) | ★ 112.9K | 45.9K |
| Earning Date | 05-16-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.77 | $0.23 |
| 52 Week High | $5.32 | $10.19 |
Technical Indicators
Market Signals| Indicator | GCDT | CLRB |
|---|---|---|
| Relative Strength Index (RSI) | 34.42 | 34.60 |
| Support Level | $0.79 | $0.29 |
| Resistance Level | $2.71 | $3.56 |
| Average True Range (ATR) | 0.37 | 0.21 |
| MACD | 0.06 | -0.06 |
| Stochastic Oscillator | 19.55 | 12.37 |
Price Performance
Historical ComparisonAbout GCDT Green Circle Decarbonize Technology Limited Ordinary Shares
Green Circle Decarbonize Technology Ltd is a company which provides advanced energy saving solutions supported by proprietary phase change thermal energy storage materials and thermal engineering services. As an advocate of decarbonization, the Company designs, develops and provides customized energy saving solutions that bring considerable economic benefits to our clients and reduce carbon emissions for a sustainable future.
About CLRB Cellectar Biosciences Inc.
Cellectar Biosciences Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of drugs for the treatment of cancer. The company's core objective is to leverage a proprietary phospholipid drug conjugate (PDC) delivery platform to develop PDCs that are designed to specifically target cancer cells and deliver improved efficacy and safety as a result of fewer off-target effects. The products under development include Iopofosine, CLR 121125 ,CLR 121225 and others. It has one operating and reportable segment focused on utilizing its PDC platform to develop drugs for the treatment of cancer.